U.S. Inflammatory Bowel Disease Treatment Market To Reach $14.1 Billion By 2030

U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends

The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 14.1 billion by 2030 and is projected to grow at a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn’s disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.

The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.

In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn’s disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.

 Request a free sample copy or view report summary: U.S. Inflammatory Bowel Disease Treatment Market Report

U.S. Inflammatory Bowel Disease Treatment Market Report Highlights

• Based on type, the Crohn’s disease segment dominated the market in 2023 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn’s disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.

• On the other hand, the ulcerative colitis segment is expected to register the fastest CAGR during the forecast period, owing to its increasing incidence rate.

• Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2023 due to their effectiveness in managing the symptoms and reducing inflammation.

• Based on route of administration, the injectable segment held the largest market share in 2023. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.

U.S. Inflammatory Bowel Disease Treatment Market Segmentation

Grand View Research has segmented the U.S. inflammatory bowel disease treatment market based on type, drug class, route of administration, distribution channel, and region:

U.S. IBD Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Crohn's Disease

• Ulcerative Colitis

U.S. IBD Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Aminosalicylates

• Corticosteroids

• TNF inhibitors

• IL inhibitors

• Anti-integrin

• JAK inhibitors

• Others

U.S. IBD Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Injectable

U.S. IBD Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

U.S. IBD Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• West

• Midwest

• Northeast

• Southwest

• Southeast

List of Key Companies in U.S. Inflammatory Bowel Disease (IBD) Treatment Market

• Biogen

• Novartis AG

• Eli Lilly and Company

• UCB S.A.

• Celltrion Inc.

• Merck & Co., Inc.

• Johnson & Johnson Services, Inc